Korea Faces FTA Dilemma As It Seeks To Balance Pricing Concerns
Executive Summary
South Korean pharma firms are facing a dilemma due to the country's Free Trade Agreement renegotiations with the US, under which drug pricing is not the only difficulty being raised by foreign companies seeking reforms. Despite ongoing government efforts to attract global pharma companies, such firms are also still finding it tough to search for alliance partners in the country.